GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Cambridge University Press (CUP)  (2)
Material
Publisher
  • Cambridge University Press (CUP)  (2)
Person/Organisation
Language
Years
  • 1
    Online Resource
    Online Resource
    Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities
    Cambridge University Press (CUP) ; 2015
    In:  Expert Reviews in Molecular Medicine Vol. 17 ( 2015)
    Details
    In: Expert Reviews in Molecular Medicine, Cambridge University Press (CUP), Vol. 17 ( 2015)
    Abstract: The Rho/ROCK pathway is involved in numerous pivotal cellular processes that have made it an area of intense study in cancer medicine, however, Rho-associated coiled-coil containing protein kinase (ROCK) inhibitors are yet to make an appearance in the clinical cancer setting. Their performance as an anti-cancer therapy has been varied in pre-clinical studies, however, they have been shown to be effective vasodilators in the treatment of hypertension and post-ischaemic stroke vasospasm. This review addresses the various roles the Rho/ROCK pathway plays in angiogenesis, tumour vascular tone and reciprocal feedback from the tumour microenvironment and explores the potential utility of ROCK inhibitors as effective vascular normalising agents. ROCK inhibitors may potentially enhance the delivery and efficacy of chemotherapy agents and improve the effectiveness of radiotherapy. As such, repurposing of these agents as adjuncts to standard treatments may significantly improve outcomes for patients with cancer. A deeper understanding of the controlled and dynamic regulation of the key components of the Rho pathway may lead to effective use of the Rho/ROCK inhibitors in the clinical management of cancer.
    Type of Medium: Online Resource
    ISSN: 1462-3994
    URL: Article
    DOI: 10.1017/erm.2015.17
    Language: English
    Publisher: Cambridge University Press (CUP)
    Publication Date: 2015
    detail.hit.zdb_id: 2035515-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Treatment of pancreatic cancer in 2022
    Cambridge University Press (CUP) ; 2023
    In:  Cambridge Prisms: Precision Medicine Vol. 1 ( 2023)
    Details
    In: Cambridge Prisms: Precision Medicine, Cambridge University Press (CUP), Vol. 1 ( 2023)
    Abstract: Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed at an advanced, incurable, stage and has an extremely poor prognosis. Systemic chemotherapy represents the standard treatment either in the pre-operative, adjuvant and palliative setting, which is associated with only modest improvement in survival. More recently, advances in cancer genomic sequencing have unravelled the molecular heterogeneity of PDAC and identified small patient subgroups harbouring unique actionable aberrations in BRCA , NTRK , NRG1 and mismatch repair genes paving the way to a more personalised approach for this tumour. However, the evolution of PDAC treatment towards a successful precision approach presents many challenges. In this review, we discuss the current standard treatments of PDAC, from early stage to advanced disease, and we illustrate the opportunities and challenges of precision medicine for this deadly cancer.
    Type of Medium: Online Resource
    ISSN: 2752-6143
    URL: Article
    DOI: 10.1017/pcm.2023.2
    Language: English
    Publisher: Cambridge University Press (CUP)
    Publication Date: 2023
    detail.hit.zdb_id: 3158049-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...